Applications of JWA polypeptide in the manufacture of anti-androgen alopecia treatments

Abstract

The objective is to solve the problems of prior art and to provide applications for JWA polypeptide in the manufacture of anti-androgenetic alopecia treatments. [Solution] The present invention relates to the use of JWA polypeptide in the manufacture of an anti-androgenetic alopecia therapeutic agent, wherein the amino acid sequence of the polypeptide is represented by I or II: I:FPGSDRF-Z; II:X-FPGSDRF-Z; where amino acid S is phosphorylated, and X and Z are amino acids or amino acid sequences, respectively. The above JWA polypeptide directly enters hair follicle cells by targeting integrin molecules and exerts effects such as regulating hair follicle proliferation and promoting hair growth within the cell; significantly shortens the hair follicle resting phase and extends the hair follicle growth phase; increases hair shaft and hair follicle volume; improves the expression level of the integrin molecule αvβ1 in target cells and can precisely activate the hair follicle stem cell signaling pathway MEK / ERK / E2F1 / SP1 / Wnt10a / 10b / β-catenin.

Claims

1. Applications of polypeptides, The aforementioned use is characterized by being for the manufacture of an anti-hair loss drug. The amino acid sequence of the polypeptide is shown in I or II: I: FPGASDRF-Z; II: X-FPGSDRF-Z; Here, amino acid S undergoes phosphorylation modification, and X and Z are amino acids or amino acid sequences, respectively; X is F, (R) 9 , (R) 9 -F,6-aminocaproic acid, 6-aminocaproic acid-F,6-aminocaproic acid-(R) 9 , 6-aminocaproic acid-(R) 9 -Selected from F; Z is (G) n -RGD, A-(G) n - Selected from RGD, where n is a non-negative integer and ranges from 0 to 10.

2. In the use described in claim 1, The aforementioned anti-hair loss agent is characterized by including an androgenic alopecia treatment drug.

3. In the use described in claim 1, The aforementioned anti-hair loss agent is characterized by its function of targeting hair follicle tissue, promoting the growth of hair follicles and hair shafts, shortening the hair follicle resting phase, extending the hair follicle growth phase, and significantly reversing the androgen-induced inhibition of hair growth.

4. In the use described in claim 1, The function of the aforementioned anti-hair loss agent is to enter hair follicle cells by targeting integrin molecules and upregulating the expression of integrin molecules on the hair follicle cell membrane; the application is characterized in that the integrin molecules mainly contain αvβ1.

5. In the use described in claim 1, The aforementioned anti-hair loss agent is characterized by its function of activating the MEK / ERK / E2F1 signaling axis to promote the expression of nuclear transcription factor SP1, and subsequently activating the hair follicle stem cell Wnt / β-catenin signaling pathway.

6. In the use described in any one of claims 1 to 5, The application is characterized in that the N-terminus of the polypeptide is acetylated and the C-terminus is amidated.

7. In the use described in any one of claims 1 to 5, The application is characterized in that the amino acid sequence of the polypeptide is one of the sequence numbers SEQ ID No. 1 to SEQ ID No.

39.

8. In the use described in any one of claims 1 to 5, The aforementioned polypeptide is characterized in that the stereochemistry of each amino acid in the sequence FPGSDRF is either L-type or D-type.

9. In the use described in any one of claims 1 to 5, The application is characterized in that the drug contains a carrier, and the carrier is a pharmaceutically acceptable carrier.

10. In the use described in any one of claims 1 to 5, An application characterized in that the dosage form of the aforementioned drug is an injectable preparation or a topical preparation.

Images